Skip to main content
. 2022 Sep 6;4:100313. doi: 10.1016/j.puhip.2022.100313

Table 3.

Log 10 Neutralising antibody titres at baseline, 14- and 28-days post second-dose vaccination (rAd5, ChAdOx1 or BBIBP-CorV).

Vaccine schedule Day
Geometric mean concentration day 28–0
0 14 28
Geometric mean (GM)
rAd26/rAd5 0.726 1.587 1.834 9.77 (5.26–18.14)
rAd26/ChAdOx1 0.881 1.972 2.131 8.98 (2.87–28.09)
rAd26/BBIBP-CorV 0.782 0.870 1.041 1.64 (0.14–4.14)
GMC ratioa
rAd26/rAd5 1.00 1.00 1.00
rAd26/ChAdOx1 2.30 (0.79–6.68) 2.34 (1.14–4.81) 2.12 (0.99–4.51)
rAd26/BBIBP-CorV 1.26 (0.60–2.62) 0.24 (0.11–0.52) 0.21 (0.09–0.47)
No. of participants 30 30 28
25b 23c 27
27 26 25
a

GMC ratio was calculated as the antilogarithm of the difference between the mean of the log10 transformed SARS-CoV-2 anti-spike IgG in the heterologous groups and that in rAd26/rAd5 (as reference category).

b

Blood samples could not be collected for 2 participants.

c

Blood samples could not be collected for 4 participants.